U.S. Markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4600+0.0500 (+3.55%)
At close: 04:00PM EST
1.5000 +0.04 (+2.74%)
After hours: 07:35PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5300
Bid1.4700 x 2900
Ask0.0000 x 2200
Day's Range1.4500 - 1.5200
52 Week Range1.2800 - 9.8000
Avg. Volume3,124,131
Market Cap184.871M
Beta (5Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.88
  • GlobeNewswire

    Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

    SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast dens

  • PR Newswire

    Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur

    Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses. The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus r

  • GlobeNewswire

    Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration

    Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant SettingSEATTLE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that it has completed a pre-investigational new drug (PIND) meeting with the FDA. The purpose of the meeting was to ob